EART failure is one of the world's leading medical problems.
ventricular dysfunction are estimated to be found in 3~4 % of the general population. 5) Although the diagnosis of heart failure may prove difficult (e.g. diverse clinical manifestations), early recognition especially from pre-clinical stages is favorable given that early diagnosis and initiation of treatment lead to improved survival. 1) Establishing of a rationale for screening cardiac dysfunction is a topic which still must be addressed. Biochemical testing would indeed be ideal as a means to screen for cardiac function given its meritorious properties as a screening test (e.g. non-invasive, cost-effective, non-specialized).
We have focused our studies on circulating B-type natriuretic peptide (BNP) levels as a biochemical parameter of cardiac function. BNP is a peptide secreted predominantly from the left ventricle in response to hemodynamic and neurohormonal stimuli. Plasma BNP levels in patients with heart failure correlate with the severity of left ventricular failure and have been suggested to be useful in predicting cardiac outcome. [7] [8] [9] [10] Through past studies, the use of BNP levels as a diagnostic, therapeutic, and prognostic marker of left ventricular failure has been firmly established. As compared to its related A-type natriuretic peptide (ANP) and derivatives, recent studies have confirmed the superiority of BNP measurements in the detection of heart failure. [11] [12] [13] Today, BNP is the most sensitive biochemical marker of cardiac function available. The role of BNP levels in assessment of cardiac function in asymptomatic subjects, however, remains unclear.
With the objective of establishing a rationale for the assessment of cardiac function by BNP levels, as a first step we examined whether BNP levels are reflective of cardiac function in a seemingly healthy population by comparing BNP levels with other cardiac indexes (chest X-ray, electrocardiogram, echocardiogram). Raised BNP levels showed significant correlation with echocardiographic parameters of both left ventricular systolic and diastolic functions.
METHODS
Study design: Subjects presenting for an annual employee health examination for 55 year olds at the Japanese pharmaceutical company Shionogi Co., Ltd. (Osaka, Japan) in 1997 were eligible for enrollment. Institutional approval and patient consent were obtained. Patients on anti-hypertensive medication were not excluded. The following patient characteristics were recorded: age; sex; history of past illness; family history; underlying cardiovascular disease including hypertension and use of medication; findings of physical examination including symptoms (e.g. shortness of breath, edema), signs (e.g. peripheral edema, pulmonary congestion), blood pressure (systolic and diastolic blood pressures, SBP and DBP, respectively) and cardiac auscultation; chest X-ray including cardiothoracic ratio (CTR); and electrocardiogram (with findings classified essentially according to the Minnesota code). In patients with elevated BNP levels (> 18.4 pg / ml), echocardiograms were also done with the ejection fraction (Teicholz method) and fractional shortening (EF and FS), and mitral inflow E-wave to A-wave ratio (E / A ratio) assessed as primary indexes reflective of the respective systolic and diastolic functions.
Additional echocardiographic parameters included the left ventricular wall thickness of the inter-ventricular septum and posterior wall (IVSTd and PWTd), aortic root and left atrial dimensions (AoD and LAD), and the left ventricular diastolic and systolic dimensions (Dd and Ds) in addition to heart rate (HR). Echocardiography was also done in age-and sex-matched controls from among patients without BNP elevations.
Serum creatinine (Cr) levels were measured in addition to BNP levels. BNP blood samples were placed in aprotinin containing tubes immediately after sampling, centrifuged at 4°C, the plasma fractions separated and then stored at − 80°C until testing. BNP measurements were done using Shionoria-BNP , an IRMA using monoclonal antibodies specific to BNP. 14) To elaborate, the capture and labeled antibodies recognize specific amino acids in the carboxyl-terminal end and ring structure of BNP, respectively. The assay showed sensitivity of 2 pg / ml, and inter-and intra-assay coefficients of variation of 6.1 % and 5.2 %, respectively. Normal reference levels were ≤ 18.4 pg / ml. Statistical analysis: Values are shown as mean ± SD. Comparison between groups was done using Welch's t-test. Regression analysis was done using linear and multiple stepwise procedures. A confidence interval of 95 % was considered significant.
RESULTS
A total of 294 patients (age 55.8 ± 3.27 years) were examined. Overall, the BNP levels were 10.8 ± 11.7 pg / ml. Forty-nine patients (16.7 %) showed elevated BNP levels of > 18.4 pg / ml (see Table I for patient demographics). Univariate analysis: Echocardiography was done in 42 consenting cases with elevated BNP levels. Linear regression analysis of echocardiographic parameters with BNP levels showed significant correlation with multiple parameters. EF (r = − 0.51, p < 0.01), FS (r = − 0.50, p < 0.01), IVSTd (r = 0.37, p < 0.05), PWTd (r = 0.49, p < 0.01), E / A (r = 0.42, p < 0.01), LAD (r = 0.56, p < 0.01) were parameters showing significant correlation (r > 0.35) (see Table II and Figure for echocardiographic statistics). All parameters excluding IVSTd were also significant (p < 0.05) against age-and sex-matched controls (n= 16). Heart rate did not show significant correlation against BNP levels (r = − 0.01, N.S.) Regression analysis of BNP levels and the CTR showed a weak but significant correlation (r = 0.23, p < 0.01). Analysis also revealed that patients with BNP levels ≥ 43 pg / ml as compared to those < 43 pg / ml showed a significant difference in CTR values (53.8 ± 2.63 vs. 47.0 ± 3.85, %, p < 0.05). Analysis further showed that subjects with CTR ≥ 50% as compared to < 50 % showed a significant difference in BNP levels (10.5 ± 10.6 vs 18.5 ± 19.8, pg / ml, p < 0.05).
Linear regression analysis of BNP levels against blood pressure, both systolic and diastolic, did not show a significant correlation. Electrocardiographic findings, however, showed the presence of ST-T abnormality to be associated with significantly elevated BNP levels (18.5 ± 9.83 vs 9.93 ± 10.2, pg / ml, p < 0.05). Significance in BNP levels was also seen when ECG findings were grouped for left ventricular hypertrophy (by voltage criteria), presence of Q-waves, ST-T abnormalities and bundle branch block, albeit within the normal range (15.8 ± 12.0 vs 9.61 ± 9.91, pg / ml, p < 0.05). Serum creatinine levels did not show a statistical relationship with BNP levels. Multivariate analysis: Multiple regression analysis was also conducted to determine factors associated with BNP levels. Both forward and backward stepwise regression analyses of all of the examined parameters showed FS, E / A, PWTd, IVSTd, Cr, DBP, Dd, Ds, AoD and HR to be associated with raised BNP levels with a coefficient of determination (r 2 ) of 88.2 %. Further multiple regression analysis (backward stepwise) was done to see whether the systolic function indexes (EF, FS) and diastolic function indexes (E / A) were associated with BNP levels (see Table IV for Figures). Indeed, EF and FS showed BNP, E / A, AoD, CTR and SBP to be associated with EF with a coefficient of determination of 64.5 %, and additionally with LAD for FS with a coefficient of determination of 62.7 %. E / A values also showed association with BNP, IVSTd, PWTd, AoD, HR and CTR with a coefficient of determination of 51.3 %. Similar results were obtained when EF was replaced by FS. These data show that BNP levels in elevated patients are reflective of both the systolic and diastolic functions. Conversely, BNP is also associated with both systolic indexes, EF and FS, and the diastolic index, E / A. Additionally, associations between left ventricular wall thickness (e.g. hypertrophy), blood pressure and creatinine levels with BNP levels were confirmed.
DISCUSSION
Our investigations began by examining BNP as a marker of cardiac function in asymptomatic subjects with the ultimate objective of understanding the role of BNP levels in early diagnosis of heart failure. Our results show that approximately 17 % of the cases in an asymptomatic population showed raised BNP levels. Elevated BNP levels reflected the cardiac function in these patients. Correlation analysis with the CTR from chest X-ray and echocardiographic parameters of systolic and diastolic functions showed moderate yet significant correlations with raised BNP levels (Table II) . Further statistical analysis done to delineate factors associated with BNP levels showed that FS, E / A, PWTd, IVSTd, Cr, DBP, Dd, Ds, AoD and HR collectively show a striking correlation of determination (r 2 ) of 88.2 %. However, as each individual clinical parameter (e.g. EF, E / A) showed only moderate correlation with BNP levels when analyzed alone, it is likely that BNP levels are reflective of the overall cardiac condition as defined by the correlating parameters (Table III) . It is reasonable to consider that the neurohormonal peptide BNP is released as a result of the multifactorial combinatorial background of parameters which affect cardiac function. Although it is difficult to ascertain the contribution of each of the individual parameters on release of BNP, importantly BNP measurements should be meritorious in understanding the overall cardiac function by use of a single parameter. BNP reflects both systolic and diastolic functions: An intriguing finding of our BNP LEVELS AND CARDIAC FUNCTION study is that BNP levels reflect both systolic and diastolic cardiac function. Although the use of BNP levels as a marker of cardiac function has been pursued, most often impaired systolic function has been the primary focus given the classical pathological profile of heart failure caused by reduced contractility. [11] [12] [13] However, impaired diastolic function is an equally important contributory factor, 3) although it often remains obscure due to lack of recognition. In fact, systolic and diastolic impairment coexist in most patients with heart failure. BNP levels have been shown to correlate with the time constant of left ventricular relaxation (τ), an index of left ventricular relaxation and thus of diastolic function as assessed by intra-cardiac manometry, 15) and the restrictive echographic filling pattern (E-wave deceleration time) in patients with systolic heart failure (EF < 0.5).
16) Additionally, serial examination of raised BNP elevations in patients receiving anthracyclines have shown the degree of BNP elevations to correlate with the decrease in the E / A ratio, 17) an echocardiographic parameter reflective of diastolic hemodynamics. 18, 19) Further support of a functional role of BNP levels in diastolic dysfunction has been shown through direct beneficial effects of BNP infusion in such pathological states. 20) We show in the present study that elevated BNP levels correlate with the diastolic echocardiographic parameter, the E / A ratio. Collectively, our studies show BNP levels to correlate with both systolic and diastolic function and thus of cardiac function overall in the tested asymptomatic population. Elevated BNP levels are diagnostic of diastolic dysfunction: A correlation between BNP levels and parameters of systolic and diastolic function is quite reasonable. Diastolic dysfunction is often seen in patients with hypertension, myocardial hypertrophy, and ischemia in addition to normal aging. Given that these factors also have been shown to affect BNP levels, 21) it is tempting to envision that BNP levels elevated in these conditions may be reflective of diastolic dysfunction based on this correlation. Aging, which affects both diastolic function and the E / A ratio, was corrected for in the study design which restricted subjects to those 55 years of age. Additionally, given our multiple regression analysis of clinical parameters associated with BNP levels in which E / A levels showed strong association with BNP, and conversely as BNP was also shown to associate strongly with the E / A ratio, the results of multi-regression analysis confirm statistically that BNP elevations are reflective at least in part of diastolic function (see Table IV ).
An important limitation of biochemical tests is often the lack of specificity of the marker to the clinical profile. BNP levels have also been reported to be elevated in patients with renal failure, left ventricular hypertrophy and myocardial disease as well as in subarachnoid hemorrhage. 22) Therefore, specificity to reflect impaired cardiac function either systolic or diastolic remains one of the limitations which makes it difficult to use BNP in the clinical situation. Interestingly, however, a number of these parameters associated with raised BNP levels (e.g. age, hypertension, left ventricular hypertrophy) as confirmed by this study may in fact reflect the diastolic component of the cardiac function and thus be diagnostic of the condition. At least for these parameters which have been considered to be 'false positives', reexamination is warranted.
Taken collectively, we have shown that BNP levels correlate with both systolic and diastolic cardiac function in an asymptomatic population. One limitation of the present study remains in the fact that despite abnormal BNP levels, only marginal abnormalities in established clinical parameters (e.g. echocardiography) were detected in the tested study population. Conversely, these data would imply that BNP levels are not only reflective of impaired systolic function as shown by past studies but also of systolic function in echographically normal subjects, suggesting that BNP levels may correlate with systolic function overall (e.g. linear relation) in addition to the diastolic function.
Although there remains the possibility that elevated BNP levels in asymptomatic subjects may be 'false positives' due to reasons not addressed in the present study or hitherto unknown mechanisms, given the fact that a lack of BNP elevations has not been reported in patients with heart disease implying a lack of 'false negatives', it is tempting to state that BNP abnormalities are suggestive of the possibility of heart disease. Although a threshold value of BNP levels for defining patients at risk for heart failure cannot be determined from the present study design, it is interesting to note that selected patients with elevated BNP levels in the studied population showed later onset of primary heart disease. Thus, in addition to use of BNP as a diagnostic marker, it may be of use as a prognostic factor for such asymptomatic patients as has been shown for patients with overt heart disease. Furthermore, as BNP measurements are non-invasive, non-technical and inexpensive as compared to other cardiac tests (e.g. echocardiography), initial screening of patients by BNP levels in addition to routine cardiac tests (e.g. ECG, CXP) may be beneficial as an additional parameter to help screen patients warranting further diagnostic investigation (e.g. echocardiography) in asymptomatic populations.
